Clear Street Markets LLC Has $100,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Clear Street Markets LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 74.0% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,212 shares of the medical research company’s stock after selling 3,443 shares during the quarter. Clear Street Markets LLC’s holdings in Edwards Lifesciences were worth $100,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. Moneta Group Investment Advisors LLC lifted its stake in Edwards Lifesciences by 104,971.3% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company’s stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares during the last quarter. Norges Bank bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at $658,390,000. Alliancebernstein L.P. lifted its stake in shares of Edwards Lifesciences by 27.5% in the 4th quarter. Alliancebernstein L.P. now owns 21,874,280 shares of the medical research company’s stock valued at $1,632,040,000 after acquiring an additional 4,712,819 shares during the last quarter. Two Sigma Advisers LP lifted its stake in shares of Edwards Lifesciences by 161.5% in the 4th quarter. Two Sigma Advisers LP now owns 3,503,803 shares of the medical research company’s stock valued at $261,419,000 after acquiring an additional 2,164,100 shares during the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of Edwards Lifesciences by 655.9% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,325,457 shares of the medical research company’s stock valued at $173,502,000 after acquiring an additional 2,017,801 shares during the last quarter. Institutional investors and hedge funds own 79.25% of the company’s stock.

Edwards Lifesciences Stock Up 0.5 %

Shares of EW traded up $0.37 during trading hours on Wednesday, hitting $76.34. The stock had a trading volume of 554,838 shares, compared to its average volume of 3,142,162. The company has a debt-to-equity ratio of 0.09, a current ratio of 3.15 and a quick ratio of 2.30. The firm has a 50 day simple moving average of $84.09 and a 200-day simple moving average of $84.15. The firm has a market capitalization of $46.41 billion, a P/E ratio of 33.62, a price-to-earnings-growth ratio of 4.12 and a beta of 1.03. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year high of $98.35.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.01. Edwards Lifesciences had a net margin of 24.56% and a return on equity of 25.43%. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.51 billion. During the same quarter last year, the firm earned $0.63 EPS. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.55 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the subject of a number of research reports. StockNews.com began coverage on Edwards Lifesciences in a research note on Thursday, August 17th. They issued a “buy” rating for the company. 58.com restated a “reiterates” rating on shares of Edwards Lifesciences in a report on Tuesday, June 27th. Jefferies Financial Group increased their price objective on Edwards Lifesciences from $103.00 to $107.00 and gave the company a “buy” rating in a report on Tuesday, July 25th. Piper Sandler increased their price objective on Edwards Lifesciences from $83.00 to $88.00 in a report on Thursday, July 27th. Finally, Citigroup increased their price objective on Edwards Lifesciences from $101.00 to $110.00 in a report on Monday, July 10th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $92.68.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Catherine M. Szyman sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $85.81, for a total transaction of $429,050.00. Following the transaction, the vice president now owns 35,056 shares of the company’s stock, valued at approximately $3,008,155.36. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Scott B. Ullem sold 7,255 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $93.27, for a total value of $676,673.85. Following the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at approximately $1,795,260.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Catherine M. Szyman sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, June 13th. The stock was sold at an average price of $85.81, for a total transaction of $429,050.00. Following the completion of the sale, the vice president now directly owns 35,056 shares in the company, valued at approximately $3,008,155.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 161,359 shares of company stock valued at $13,515,345. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.